Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) has received a consensus rating of “Hold” from the five analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $6.00.
SPRO has been the subject of several research analyst reports. HC Wainwright boosted their price objective on shares of Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Cantor Fitzgerald initiated coverage on Spero Therapeutics in a research report on Wednesday, October 28th. They issued an “overweight” rating and a $6.00 price objective on the stock. Zacks Research raised Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Weiss Ratings downgraded Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, October 26th. Finally, Wall Street Zen downgraded Spero Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday.
Check Out Our Latest Analysis on SPRO
Institutional Trading of Spero Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alphabet Inc. acquired a new position in Spero Therapeutics during the 2nd quarter valued at about $1,967,000. BlackRock Inc. bought a new position in shares of Spero Therapeutics in the 2nd quarter valued at about $1,314,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Spero Therapeutics in the 2nd quarter valued at about $36,000. Global Retirement Partners LLC bought a new position in shares of Spero Therapeutics in the 2nd quarter valued at about $55,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Spero Therapeutics during the 2nd quarter worth approximately $632,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.
Spero Therapeutics Stock Performance
Shares of NASDAQ SPRO opened at $1.04 on Wednesday. Spero Therapeutics has a 1-year low of $1.03 and a 1-year high of $3.08. The company has a market cap of $60.57 million, a PE ratio of 9.45 and a beta of 1.59. The company has a 50-day moving average of $1.17 and a two-hundred day moving average of $1.97.
Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. As a group, equities research analysts forecast that Spero Therapeutics will post -0.97 earnings per share for the current year.
About Spero Therapeutics
Spero Therapeutics, Inc (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.
Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.
Featured Stories
- Five stocks we like better than Spero Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
